University of Edinburgh
Targeting USP18 to enhance type I interferon signalling and immune activation in the tumour microenvironment of triple-negative breast cancer
Abstract
dc:description.abstractTriple-negative breast cancer (TNBC) represents one of the most aggressive and therapeutically challenging subtypes of breast cancer, characterized by the absence of oestrogen receptor (ER), progesterone receptor (PR), and HER2 expressions. TNBC accounts for approximately 15-20% of all breast cancer cases and is associated with a poor prognosis, high rates of recurrence, and limited treatment options. Although immune checkpoint inhibitors (ICIs) have emerged as a promising therapeutic approach, their clinical benefit remains modest even when administered in combination with standard chemotherapeutic agents. This limited efficacy has largely been attributed to the presence of immunologically “cold” tumour microenvironments (TMEs), characterized by reduced immune infiltration, impaired antigen presentation, and an immunosuppressive cytokine response. Overcoming these barriers and reprogramming “cold” tumours into “hot,” immune-responsive phenotypes may improve TNBC therapy. One promising strategy for enhancing anti-tumour immunity involves modulating the Type I interferon (IFN) pathway, a central regulator of immune responses. Moreover, Type I IFN has a negative regulator called Ubl carboxyl-terminal hydrolase 18 (USP18) which plays a critical role in maintaining immune tolerance in cells. USP18 regulates Type I IFN by removing ISG15 conjugates from target proteins and disrupting the interaction between IFNAR2 and STAT2. Therefore, USP18 dampens downstream IFN signalling. Dysregulation of USP18 has been reported across multiple cancers, where its overexpression contributes to immune evasion and therapy resistance. In this study, we investigated the impact of USP18 inhibition on TNBC tumour immunogenicity and responsiveness to IFN-driven immune activation by using both genetic ablation and catalytic inactivation of USP18 as models. Our findings demonstrate that USP18 loss significantly enhances Type I IFN signalling in TNBC cells, resulting in sustained phosphorylation of STAT1 and STAT2 and prolonged activation of IFN-stimulated gene (ISG) expression. This heightened responsiveness of Type I IFN promotes antigen presentation through an upregulation of MHC class I molecules and cytokine production, such as HLA-A, HLA-B, HLA-C, CXCL10, and CCL20. Furthermore, USP18 depletion increases the expression of pro-apoptotic death receptors, such as Fas (CD95) and TRAIL receptors, sensitising cancer cells to immune-mediated killing by NK cells in co-culture study. To characterize the broader immunological consequences of USP18 loss, we performed integrated proteomic profiling and immunophenotyping in vivo. These analyses revealed that USP18 inhibition remodels the tumour immune landscape, driving a shift from an immunosuppressive to an immunostimulatory microenvironment. Specifically, we observed a significant increase in CD8⁺ cytotoxic T lymphocytes (CTLs) infiltration, enhanced recruitment of Th1-polarized CD4⁺ T cells, activation of cDC1s, and expansion of pro-inflammatory macrophages. Additionally, natural killer (NK) cell abundance was elevated, suggesting a broader activation of both adaptive and innate immune responses. Together, these changes with a marked reduction in tumour growth in immunocompetent BALB/c mouse models showed that targeting USP18 promotes IFN-driven immune activation mediating tumour growth suppression. These results establish USP18 as a central regulator of immune escape in TNBC and demonstrate that its inhibition facilitates a durable IFN-driven anti-tumour immune response. Collectively, our study identifies USP18 as a promising therapeutic target in TNBC, capable of reprogramming immunologically “cold” tumours into “hot,” immune-responsive states by enhancing Type I IFN signalling, boosting antigen presentation, and promoting effector immune cell recruitment. These findings highlight the translational potential of USP18 inhibition as a novel immunomodulatory strategy that could synergize with immune checkpoint blockade, radiotherapy, and other immunotherapeutic approaches to improve clinical outcomes for patients with TNBC.
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Chutoe, Chartinun
- Advisors dc:contributor.advisor
-
- Von Kriegsheim, Alex
- Brunton, Val
Subjects
dc:subject × 4Rights
- Language dc:language.iso
- en
Identifiers
dc:identifier.*- Identifier URI
- https://doi.org/10.7488/era/7366